Results 61 to 70 of about 7,047 (156)

Covalent binding energies of the compounds to human XPO1 (CRM1).

, 2023
Covalent binding energies of the compounds to human XPO1 (CRM1).
Mahmoud Shehata (9574695), David Olagnier (205583), Andreas Pavlou (15272395), Ulrich Martin (62121), Stephan Pleschka (85578), Fabio Begnini (4795374), Anna K. H. Hirsch (7491110), Naziia Kurmasheva (11575748), Sylvia Merkert (16558010), Ruth Olmer (3744291), Thomas B. Poulsen (2478502), Anders E. Kiib (16558004), Chutao Chen (16558007), Fakhar H. Waqas (16557998), Walid A. M. Elgaher (8355894), Antoine Lacour (16558001), Frank Pessler (52000), Julia Dahlmann (4919113)   +17 more
core   +1 more source

Mutant NPM1 in Acute Myeloid Leukemia Initiation and Maintenance

Aging and Cancer, Volume 7, Issue 3, Page 109-124, September 2026.
NPM1 mutations drive acute myeloid leukemia by acting as neomorphic transcriptional regulators that cooperate with Menin–MLL and XPO1 to sustain HOX/MEIS1 expression and block differentiation. Targeting these mutant‐specific transcriptional dependencies provides a rational therapeutic strategy for NPM1‐mutated AML.
Yanan Jiang, Zhong Fan, Runmeng Liu, Xiaotian Zhang   +3 more
wiley   +1 more source

Venetoclax for elderly patients with acute myeloid leukaemia unfit for intensive chemotherapy: Prospects, resistance mechanisms and management strategies

Clinical and Translational Medicine, Volume 16, Issue 9, September 2026.
Resistance to venetoclax has become a critical bottleneck limiting its long‐term clinical benefits. A thorough understanding of the underlying resistance mechanisms and the development of novel strategies to overcome resistance are central to improving survival outcomes in elderly AML patients. Abstract To date, the treatment of acute myeloid leukaemia
Jinlin Zhang, Jile Liu, Mohan Zhao, Xiaoyu Zhang, Linlin Liu, Mengnan Li, Changze Cao, Rui Zhang, Mingfeng Zhao   +8 more
wiley   +1 more source

Positive Feedback Regulation between KLF5 and XPO1 Promotes Cell Cycle Progression of Basal like Breast Cancer

Advanced Science
Basal‐like breast cancer (BLBC), overlapping with the subgroup of estrogen receptor (ER), progesterone receptor (PR), and HER2 triple‐negative breast cancer, has the worst prognosis and limited therapeutics. The XPO1 gene encodes nuclear export protein 1,
Yu Tang, Rui Liu, Jing Zhu, Qian He, Chenglong Pan, Zhongmei Zhou, Jian Sun, Fubing Li, Longlong Zhang, Yujie Shi, Jing Yao, Dewei Jiang, Ceshi Chen   +12 more
doaj   +1 more source

Ribosomal Biogenesis and Translational Flux Inhibition by the Selective Inhibitor of Nuclear Export (SINE) XPO1 Antagonist KPT-185.

PLoS ONE, 2015
Mantle cell lymphoma (MCL) is an aggressive B-cell lymphoma characterized by the aberrant expression of several growth-regulating, oncogenic effectors. Exportin 1 (XPO1) mediates the nucleocytoplasmic transport of numerous molecules including oncogenic ...
Yoko Tabe, Kensuke Kojima, Shinichi Yamamoto, Kazumasa Sekihara, Hiromichi Matsushita, Richard Eric Davis, Zhiqiang Wang, Wencai Ma, Jo Ishizawa, Saiko Kazuno, Michael Kauffman, Sharon Shacham, Tsutomu Fujimura, Takashi Ueno, Takashi Miida, Michael Andreeff   +15 more
doaj   +1 more source

Autoimmunity: Molecular Mechanisms, Biomarkers, and Therapeutic Opportunities

MedComm, Volume 7, Issue 9, September 2026.
Major types of immunometabolism, epigenetics, posttranscriptional regulation, and functional reprogramming involved in autoimmune diseases. The roles of immunometabolism, epigenetics, posttranscriptional regulation, and functional reprogramming in autoimmune diseases have been a major research focus in recent years.
Jialong Kuang, Yin Zhu, Fang Xu, Yongjing Liu, Yuan Li, Ling Yuan, Liqin Wei, Bo Huang, Yan Chen, Pei Huang, Zuochen Du   +10 more
wiley   +1 more source

XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53

Journal of Hematology & Oncology, 2020
The XPO1 inhibitor selinexor was recently approved in relapsed/refractory DLBCL patients but only demonstrated modest anti-DLBCL efficacy, prompting us to investigate the prognostic effect of XPO1 in DLBCL patients and the rational combination therapies ...
Manman Deng, Mingzhi Zhang, Zijun Y. Xu-Monette, Lan V. Pham, Alexandar Tzankov, Carlo Visco, Xiaosheng Fang, Govind Bhagat, Feng Zhu, Karen Dybkaer, April Chiu, Wayne Tam, Youli Zu, Eric D. Hsi, William W. L. Choi, Jooryung Huh, Maurilio Ponzoni, Andrés J. M. Ferreri, Michael B. Møller, Benjamin M. Parsons, J. Han van Krieken, Miguel A. Piris, Jane N. Winter, Fredrick Hagemeister, Lapo Alinari, Yong Li, Michael Andreeff, Bing Xu, Ken H. Young   +28 more
doaj   +1 more source

Study of XPO1 abnormalities in B cell lymphomas

, 2020
L'exportine-1 (ou XPO1) joue un rôle clé dans le transport de nombreux ARN et près de 200 protéines cargos. La mutation « hot-spot » XPO1-E571K est présente chez près de 25% des patients atteints par le lymphome primitif du médiastin (PMBL) et la forme ...
Miloudi, Hadjer
core  

XPO1/CRM1 inhibition causes antitumor effects by mitochondrial accumulation of eIF5A

, 2015
Purpose: XPO1 inhibitors have shown promise for cancer treatment, and yet the underlying mechanisms for the antitumor effects are not well understood. In this study, we explored the usefulness of selective inhibitors of nuclear export (SINE) compounds ...
Wu, Sherry Y., Wiktorowicz, John E., Gharpure, Kshipra M., Dalton, Heather J., Previs, Rebecca A., Sood, Anil K., Coleman, Robert L., Miyake, Takahito, Shacham, Sharon, Hisamatsu, Takeshi, Cho, Min Soon, Hawke, David H., Pradeep, Sunila, Wen, Yunfei, McCauley, Dilara, Kang, Yu, Zand, Behrouz, Hu, Wei, Rupaimoole, Rajesha, Taylor, Morgan L., Liu, Tao, Nagaraja, Archana S.   +21 more
core   +1 more source

The nuclear export protein exportin‐1 in solid malignant tumours: From biology to clinical trials

Clinical and Translational Medicine
Background Exportin‐1 (XPO1), a crucial protein regulating nuclear‐cytoplasmic transport, is frequently overexpressed in various cancers, driving tumor progression and drug resistance. This makes XPO1 an attractive therapeutic target.
Chuanxi Lai, Lingna Xu, Sheng Dai
doaj   +1 more source